 Patrick Hume
Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cigarette Smoking | 2 | 2022 | 91 | 1.310 |
Why?
| | Lung | 9 | 2024 | 3926 | 0.890 |
Why?
| | Macrophages, Alveolar | 3 | 2024 | 389 | 0.760 |
Why?
| | Perfusion | 1 | 2021 | 197 | 0.670 |
Why?
| | Pressure | 1 | 2021 | 237 | 0.660 |
Why?
| | Pulmonary Emphysema | 1 | 2022 | 275 | 0.640 |
Why?
| | Blood Vessels | 1 | 2021 | 187 | 0.630 |
Why?
| | Polyethylene Glycols | 3 | 2012 | 587 | 0.590 |
Why?
| | Pulmonary Alveoli | 1 | 2021 | 400 | 0.580 |
Why?
| | Patient Care Planning | 1 | 2018 | 146 | 0.560 |
Why?
| | Hydrogels | 4 | 2023 | 629 | 0.540 |
Why?
| | Shock, Septic | 1 | 2018 | 209 | 0.510 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 983 | 0.450 |
Why?
| | Hospital Mortality | 1 | 2018 | 846 | 0.430 |
Why?
| | Metalloporphyrins | 1 | 2011 | 101 | 0.350 |
Why?
| | Coated Materials, Biocompatible | 1 | 2011 | 59 | 0.350 |
Why?
| | Superoxides | 1 | 2011 | 201 | 0.350 |
Why?
| | Biomimetic Materials | 1 | 2011 | 69 | 0.350 |
Why?
| | Mice | 13 | 2025 | 16915 | 0.340 |
Why?
| | fas Receptor | 1 | 2010 | 95 | 0.330 |
Why?
| | Photochemistry | 1 | 2010 | 132 | 0.320 |
Why?
| | Polymers | 2 | 2011 | 477 | 0.320 |
Why?
| | Superoxide Dismutase | 1 | 2011 | 342 | 0.310 |
Why?
| | Dendritic Cells | 1 | 2012 | 479 | 0.300 |
Why?
| | Biocompatible Materials | 1 | 2012 | 388 | 0.290 |
Why?
| | T-Lymphocytes | 3 | 2012 | 1933 | 0.290 |
Why?
| | Animals | 14 | 2025 | 35307 | 0.250 |
Why?
| | Fucosyltransferases | 1 | 2025 | 32 | 0.230 |
Why?
| | Chemokine CXCL12 | 1 | 2025 | 79 | 0.230 |
Why?
| | Bronchial Hyperreactivity | 1 | 2025 | 105 | 0.230 |
Why?
| | Mucus | 1 | 2025 | 77 | 0.230 |
Why?
| | Apoptosis | 2 | 2011 | 2498 | 0.230 |
Why?
| | Bioengineering | 1 | 2024 | 19 | 0.220 |
Why?
| | Orthomyxoviridae Infections | 1 | 2024 | 67 | 0.220 |
Why?
| | Leukocytes | 2 | 2022 | 306 | 0.220 |
Why?
| | Vascular System Injuries | 1 | 2023 | 73 | 0.200 |
Why?
| | X-Ray Microtomography | 1 | 2022 | 83 | 0.190 |
Why?
| | Precancerous Conditions | 1 | 2023 | 163 | 0.190 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2022 | 40 | 0.190 |
Why?
| | Vaping | 1 | 2023 | 54 | 0.190 |
Why?
| | Neuropeptides | 1 | 2022 | 71 | 0.190 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2022 | 58 | 0.190 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 89 | 0.180 |
Why?
| | Repressor Proteins | 1 | 2024 | 406 | 0.180 |
Why?
| | Fixatives | 1 | 2021 | 15 | 0.180 |
Why?
| | Mice, Inbred C57BL | 4 | 2025 | 5439 | 0.180 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2022 | 274 | 0.170 |
Why?
| | Leukosialin | 1 | 2020 | 14 | 0.170 |
Why?
| | Mannose-Binding Lectins | 1 | 2020 | 11 | 0.170 |
Why?
| | Optical Devices | 1 | 2020 | 13 | 0.170 |
Why?
| | Immunoglobulin G | 1 | 2024 | 848 | 0.170 |
Why?
| | Lung Injury | 1 | 2023 | 210 | 0.170 |
Why?
| | Lectins, C-Type | 1 | 2020 | 71 | 0.170 |
Why?
| | Medical Writing | 1 | 2019 | 2 | 0.170 |
Why?
| | Killer Cells, Natural | 1 | 2023 | 427 | 0.170 |
Why?
| | Cell Count | 1 | 2020 | 311 | 0.160 |
Why?
| | Neutrophils | 1 | 2025 | 1207 | 0.160 |
Why?
| | Disease Models, Animal | 3 | 2025 | 4057 | 0.150 |
Why?
| | Pneumonia | 1 | 2024 | 616 | 0.150 |
Why?
| | Influenza, Human | 1 | 2024 | 601 | 0.150 |
Why?
| | Boston | 1 | 2018 | 87 | 0.150 |
Why?
| | Receptors, Cell Surface | 1 | 2020 | 380 | 0.140 |
Why?
| | Lung Diseases | 1 | 2024 | 739 | 0.140 |
Why?
| | Tissue Donors | 1 | 2020 | 391 | 0.140 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 857 | 0.140 |
Why?
| | Mice, Transgenic | 1 | 2022 | 2117 | 0.140 |
Why?
| | Humans | 16 | 2025 | 129248 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 273 | 0.130 |
Why?
| | Linear Models | 1 | 2018 | 819 | 0.120 |
Why?
| | Immunohistochemistry | 1 | 2020 | 1691 | 0.120 |
Why?
| | Disease Management | 1 | 2018 | 588 | 0.110 |
Why?
| | Macrophages | 1 | 2022 | 1484 | 0.110 |
Why?
| | Biomedical Research | 1 | 2019 | 637 | 0.110 |
Why?
| | Research Design | 1 | 2019 | 1043 | 0.110 |
Why?
| | Flow Cytometry | 2 | 2022 | 1155 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2020 | 3377 | 0.100 |
Why?
| | Asthma | 1 | 2025 | 2220 | 0.090 |
Why?
| | Glucose Oxidase | 1 | 2011 | 26 | 0.090 |
Why?
| | Coculture Techniques | 1 | 2012 | 223 | 0.090 |
Why?
| | 3T3 Cells | 1 | 2011 | 153 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2012 | 157 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2342 | 0.090 |
Why?
| | Materials Testing | 1 | 2012 | 343 | 0.080 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 588 | 0.080 |
Why?
| | Jurkat Cells | 1 | 2010 | 134 | 0.080 |
Why?
| | Interleukin-10 | 1 | 2012 | 300 | 0.080 |
Why?
| | Cell Adhesion | 1 | 2010 | 452 | 0.080 |
Why?
| | Mice, Knockout | 2 | 2025 | 2871 | 0.070 |
Why?
| | Middle Aged | 2 | 2020 | 31087 | 0.070 |
Why?
| | Endothelial Cells | 2 | 2025 | 746 | 0.070 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1109 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 833 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 854 | 0.070 |
Why?
| | Female | 4 | 2025 | 68543 | 0.060 |
Why?
| | Genetic Enhancement | 1 | 2006 | 5 | 0.060 |
Why?
| | DNA Probes | 1 | 2006 | 61 | 0.060 |
Why?
| | Cell Line | 1 | 2011 | 2779 | 0.060 |
Why?
| | Male | 3 | 2025 | 63501 | 0.060 |
Why?
| | Protein Engineering | 1 | 2006 | 106 | 0.060 |
Why?
| | Mucin 5AC | 1 | 2025 | 69 | 0.060 |
Why?
| | Glycosylation | 1 | 2025 | 152 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2012 | 1887 | 0.060 |
Why?
| | Escherichia coli Proteins | 1 | 2006 | 178 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 756 | 0.050 |
Why?
| | Urethane | 1 | 2023 | 41 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2011 | 4076 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2024 | 76 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2024 | 164 | 0.050 |
Why?
| | Mucin-5B | 1 | 2025 | 214 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 160 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 96 | 0.050 |
Why?
| | Regeneration | 1 | 2024 | 181 | 0.050 |
Why?
| | Ceramides | 1 | 2023 | 112 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 308 | 0.050 |
Why?
| | Tidal Volume | 1 | 2022 | 84 | 0.050 |
Why?
| | Positive-Pressure Respiration | 1 | 2022 | 76 | 0.050 |
Why?
| | Escherichia coli | 1 | 2006 | 766 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 336 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 621 | 0.050 |
Why?
| | Adolescent | 1 | 2020 | 20303 | 0.040 |
Why?
| | Aged | 1 | 2020 | 22032 | 0.040 |
Why?
| | Dronabinol | 1 | 2023 | 203 | 0.040 |
Why?
| | Time Factors | 1 | 2011 | 6543 | 0.040 |
Why?
| | NF-kappa B | 1 | 2024 | 665 | 0.040 |
Why?
| | Tissue Engineering | 1 | 2024 | 388 | 0.040 |
Why?
| | Stem Cells | 1 | 2024 | 574 | 0.040 |
Why?
| | Financing, Organized | 1 | 2019 | 29 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2022 | 644 | 0.040 |
Why?
| | Signal Transduction | 1 | 2012 | 4926 | 0.040 |
Why?
| | Respiration, Artificial | 1 | 2022 | 613 | 0.040 |
Why?
| | Adult | 1 | 2020 | 35495 | 0.040 |
Why?
| | Teaching | 1 | 2019 | 214 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2025 | 2737 | 0.030 |
Why?
| | Hypoxia | 1 | 2022 | 1084 | 0.030 |
Why?
| | United States | 1 | 2023 | 13828 | 0.020 |
Why?
| | Drug Tolerance | 1 | 2006 | 90 | 0.020 |
Why?
| | Heat-Shock Response | 1 | 2006 | 72 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2006 | 361 | 0.010 |
Why?
| | DNA, Bacterial | 1 | 2006 | 321 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2006 | 1304 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2006 | 3079 | 0.010 |
Why?
| | Mutation | 1 | 2006 | 3710 | 0.010 |
Why?
|
|
Hume's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|